微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志 ›› 2016, Vol. 8 ›› Issue (2): 96-99.doi: 10.3969/j.issn.1674-5671.2016.02.06

• 临床研究 • 上一篇    下一篇

替吉奥联合奥沙利铂动脉灌注及栓塞治疗晚期胃癌的临床疗效

  

  1. 甘肃省第二人民医院肿瘤科
  • 出版日期:2016-04-25 发布日期:2016-05-13
  • 通讯作者: 邵鹏 shaopeng20071111@163.com
  • 基金资助:

    甘肃省兰州市科技计划项目（2012-1-38）

Clinical observations of S-1 combined with transarterial infusion with oxaliplatin and em-bolism to treat advanced gastric cancer

  • Online:2016-04-25 Published:2016-05-13

PDF (PC)

341

赞

被引次数

1

摘要：

目的 观察替吉奥（S-1）联合奥沙利铂（OXA）动脉灌注及栓塞治疗晚期胃癌的疗效及安全性。方法　将59例晚期胃癌患者按随机数字表法分为两组，观察组30例，给予S-1口服+OXA动脉灌注及栓塞；对照组29例，给予OXA+5-氟尿嘧啶（5-FU）动脉灌注及栓塞，每6周介入治疗1次。连续2次介入治疗后评价疗效及不良反应。结果　观察组和对照组有效率（RR）分别为50.0 %和44.8%，疾病控制率（DCR）分别为93.3%和68.9%，中位疾病进展时间（TTP）分别为8.1个月和5.3个月，中位生存时间分别为14.3个月和13.2个月，两组DCR及中位TTP差异有统计学意义（P<0.05）。两组栓塞综合征发生率比较差异无统计学意义（P>0.05），观察组白细胞减少和腹泻发生率较对照组明显下降（33.3% vs 62.1% 和20.0% vs 51.7%），差异有统计学意义（P<0.05）。结论　S-1联合OXA动脉灌注及栓塞治疗晚期胃癌的近期疗效较好，不良反应较少，值得临床推广应用。

关键词: 晚期胃肿瘤, 替吉奥, 奥沙利铂, 动脉灌注, 栓塞, 疗效

Abstract:

Objective To evaluate the efficacy and safety of S-1 combined with transarterial infusion with oxaliplatin and embolism therapy for treating advanced gastric cancer. Methods Patients with advanced gastric cancer（n=59） were divided into two groups：30 patients received S-1 orally as well as transarterial chemoembolization with oxaliplatin，while 29 patients in the control group received transarterial chemoembolization with oxaliplatin and fluorouracil，once every 6 weeks. Efficacy and toxicity were evaluated after two treatments. Results The remission rate was 50.0% in the S-1 group and 44.8% in the control group. The disease control rate was significantly higher in the S-1 group（93.3%） than in the control group （68.9%，P<0.05），and median time to progression was longer in the S-1 group （8.1 vs 5.3 months，P<0.05）. Median overall survival was slightly higher in the S-1 group（14.3 vs 13.2 months）. Similar proportions of patients in both groups experienced embolism syndrome（P>0.05），whereas significantly lower proportions of S-1 patients eperienced leucopenia（62.1% vs 33.3%） and diarrhea（51.7% vs 20%，P<0.05）. Conclusion S-1 combined with transarterial infusion of oxaliplatin and embolism shows better efficacy and fewer adverse reactions in patients with advanced gastric cancer than transarterial chemoembolization with oxaliplatin and fluorouracil. These results indi-cate the need for further clinical studies.

Key words: Advanced gastric neoplasm, S-1, Oxaliplatin, Transarterial infusion, Embolism, Efficacy